Health Care • Biotechnology: Pharmaceutical Preparations
$18.69 ▼ -0.06
(-0.32%)
MKT CAP: $484.5M • VOL: 511.0K
52W L $7 52W H $42
ROARABLE / RQD
E • 29/100
PIOTROSKI
3 / 9
FTH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.3M | -$32.6M | -$37.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$21.1M | -$30.2M | -$34.1M |
| EBITDA (Normalized) | -$22.3M | -$32.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$20.5M | -$24.7M | -$32.0M |
| Capital Expenditures (CapEx) | $16.0K | $146.0K | — |
| Free Cash Flow (FCF) | -$20.5M | -$24.8M | -$32.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.7M | $10.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $18.6M | $38.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FTH.